Skip Navigation



Carcinogenesis Advance Access published online on January 16, 2006

Carcinogenesis, doi:10.1093/carcin/bgi346
This Article
Right arrow Advance Access manuscript (PDF) Freely available
Right arrow All Versions of this Article:
27/5/1105    most recent
bgi346v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Kim, D. J.
Right arrow Articles by Peters, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kim, D. J.
Right arrow Articles by Peters, J. M.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published by Oxford University Press 2006
Received October 17, 2005
Revised November 23, 2005
Accepted January 13, 2006

CARCINOGENESIS

Inhibition of chemically-induced skin carcinogenesis by sulindac is independent of peroxisome proliferator-activated receptor-{beta}/{delta} (PPAR{beta}/{delta})

Dae J. Kim 1, K. Sandeep Prabhu 2, Frank J. Gonzalez 3, and Jeffrey M. Peters 1 *

1 Department of Veterinary and Biomedical Sciences and The Center for Molecular Toxicology and Carcinogenesis, The Pennsylvania State University, University Park, PA, 16802; Graduate Program in Molecular Toxicology, The Huck Institutes of the Life Sciences, The Pennsylvania State University, University Park, PA, 16802
2 Department of Veterinary and Biomedical Sciences and The Center for Molecular Toxicology and Carcinogenesis, The Pennsylvania State University, University Park, PA, 16802
3 Laboratory of Metabolism, National Cancer Institute, Bethesda, MD, 20892

* To whom correspondence should be addressed.
Jeffrey M. Peters, E-mail: jmp21{at}psu.edu


   Abstract

Inhibition of cyclooxygenase-2 (COX2) by non-steroidal anti-inflammatory drugs (NSAID) is known to suppress skin carcinogenesis. It was further suggested that inhibition of COX2-derived prostaglandins by NSAIDs could reduce levels of putative endogenous ligands of peroxisome proliferator-activated receptor-{beta} (PPAR{beta}), and these ligands could potentiate tumorigenesis. However, it is currently unclear whether ligand activation of PPAR{beta} either inhibits or potentiates carcinogenesis. The present studies were designed to examine the mechanism of NSAID-mediated chemoprevention in skin, and in particular, to determine the role of PPAR{beta} in this process. A two-stage skin carcinogenicity bioassay was performed using wild-type and PPAR{beta}-null mice that were fed either a control diet, or one containing 0.32 g sulindac/kg diet. Significant inhibition of chemically-induced skin carcinogenesis was observed in both wild-type and PPAR{beta}-null mice, and this was associated with a marked decrease in the concentration of skin prostaglandins including PGE2 and PGI2. Results from these studies demonstrate that inhibition of COX2 by dietary sulindac in mouse skin can effectively inhibit chemically-induced skin carcinogenesis, and suggest that the mechanism underlying this chemopreventive effect is independent of PPAR{beta}. Additionally, results from these studies do not support the hypothesis that ligand activation of PPAR{beta} by COX-derived metabolites potentiates chemically-induced skin carcinogenesis.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
J. Lipid Res.Home page
M. Schmuth, Y. J. Jiang, S. Dubrac, P. M. Elias, and K. R. Feingold
Thematic Review Series: Skin Lipids. Peroxisome proliferator-activated receptors and liver X receptors in epidermal biology
J. Lipid Res., March 1, 2008; 49(3): 499 - 509.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
H. E. Hollingshead, M. G. Borland, A. N. Billin, T. M. Willson, F. J. Gonzalez, and J. M. Peters
Ligand activation of peroxisome proliferator-activated receptor-{beta}/{delta} (PPAR{beta}/{delta}) and inhibition of cyclooxygenase 2 (COX2) attenuate colon carcinogenesis through independent signaling mechanisms
Carcinogenesis, January 1, 2008; 29(1): 169 - 176.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.